Member Info for Kaneonaim

More ? Trades gone through at 8.30 imo the size should have made the price tick down if they were sells???

Tsx at 559k volume dropped on open now back flat!!

The buyers out way the sellers by £500k that’s not pi’s imo!!

# Trades 144
Vol. Sold 2,695,454
Sold Value £225.07k
Vol. Bought 7,509,200
Bought Value £627.02k

Someone has got their wallet out today!!

Brent $70
Wti 67

SAUDI ARABIA CONFIRMS ATTEMPTED ATTACK AT ARAMCO FACILITY: SPA

As if oil needed more upside!! $100 could be closer than we think!!!

Repsol Sinopec Resources UK Limited has formed an innovative partnership with energy service providers TechnipFMC and Petrofac, creating an industry alliance which seeks to maximise the recovery of oil and gas from the UK Continental Shelf (UKCS).

The partnership will offer the owners of oil and gas discoveries near Repsol Sinopec’s existing North Sea infrastructure hubs an integrated, technically robust and commercially flexible solution to meet their near to mid-term development objectives.

Under the terms of the partnership, TechnipFMC will deploy its *iFEED® front-end engineering and design solution and its integrated subsea business model, **iEPCI™, whilst Petrofac will provide all topsides engineering and operations support. Repsol Sinopec will provide access to its facilities under the industry-led infrastructure code of practice. Together, the group offers decades of subsea and topsides engineering, project management and operating expertise to create an all-encompassing offering, from the well head to export route.

José Luis Muñoz, CEO Repsol Sinopec said: “As an industry we must get better at recognising the benefits of utilising existing North Sea infrastructure to maximise the economic recovery of the basin, minimise carbon emissions and transition to a lower carbon economy. This industry collaboration brings together three well respected, experienced companies that have the resources, drive and ambition to support the continued success of the industry for many years to come.”

Nick Shorten, Managing Director of Petrofac’s Engineering and Production Services, West business said: “With more than three billion barrels locked in marginal fields across the UKCS, small pools represent a big opportunity. Industry level collaborations such as this will drive the standardisation required to reduce the time and cost of tie-back developments. Petrofac is thrilled to combine the asset knowledge gained as Repsol Sinopec’s operations and maintenance partner, with our engineering and project management expertise in support of this exciting collaboration.”

Worth watching this if you haven’t already “North Sea assets potential 30k bpd” 3minute 20 seconds

https://www.youtube.com/watch?v=XF_gndkyuWg&feature=youtu.be

NFX closed down 1.96 percent on Friday, March 5, 2021, on 1.46 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

What’s the 2 trade all about?

A small set of investors that previously focused on the oil and gas industry are eyeing an opportunity in a gas currently fetching a high price

In a corner of Saskatchewan where drillers had previously spudded wells for oil and gas extraction, investors are pouring money into a previously untapped resource, which emits no carbon and could diversify the province’s economy.

“There’s a fair amount of capital out there that understands the technology, understands drilling, understands all of that but is a little nervous about the oil and gas space,” said Andrew Davidson, president and CEO of Royal Helium Ltd., a TSX-Venture exchange listed company that last year raised $7.5 million to drill three wells near Climax, Sask.

https://financialpost.com/commodities/energy/beyond-balloons-saskatchewan-emerges-as-a-helium-hub-as-drilling-ramps-up

Interesting that Nintedanib is also used to treat lung cancer!!
Nintedanib, sold under the brand names Ofev and Vargatef, is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer.

If find this website useful. When I first bought I3e were rated F now they rate them B

I3E closed up 0.65 percent on Wednesday, March 3, 2021, on 85 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

http://lse.swingtradebot.com/equities/I3E:LSE

Was hoping for farm out news for my birthday! Can wait though hopefully we get it before the next

GLA

Nice to have you back fast food!!

https://m.youtube.com/watch?v=WNK_ZSwkYVs

Lots of 200k buys today!

Well said bertiebassett they guy’s just trying to blame everyone other than himself!!

A little patience and this will come good some people haven’t got the mentality for this game that’s why so many lose!!! All he’s doing is seeing red and getting frustrated and wants to blame everyone other than the one who clicked the button

250k buy at 7.95

Not sure if this has been shared it’s from 7th January it’s a news article and it says nuformix and ebers are still working together to to make cannabinoid cocrystals!! It won’t let me copy and paste but here’s the link

https://www.pressreader.com/canada/stockwatch-daily/20210108/282252373160406

The key point is who imaging biometrics is working with on these projects!

The grant in collaboration with BNI includes working with major scanner vendors (GE, Siemens, and Philips) to harmonise the way perfusion MRI data is collected and post-processed. The involvement of the major scanner vendors is exciting and very positive, and the Company looks forward to their continued collaboration and support.

QIN Reference Listing:

Published Manuscripts

Schmainda KM, Zhang Z, Prah M, Snyder BS, Gilbert MR, Sorensen AG, Barboriak DP, & Boxerman JL. (2015). “Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multi-center trial.” Neuro-Oncology,17(8):1148-56. PMID: 25646027.

Prah MA, Stufflebeam SM, Paulson ES, Kalpathy-Cramer J, Gerstner ER, Batchelor TT, Barboriak DP, Rosen BR, Schmainda KM. “Repeatability of standardized and normalized relative CBV in patients with newly diagnosed glioblastoma.” Am J Neuroradiol 36(9):1654-61 (2015). PMID: 26066626.

Jafari-Khouzani K, Emblem KE, Kalpathy-Cramer J, Bjornerud A, Vangel M, Gerstner E, Schmainda KM, Paynabar K, Wu O, Wen PY, Batchelor T, Rosen B, Stufflebeam SM. “Repeatability of cerebral perfusion using dynamic susceptibility contrast MRI on glioblastoma patients.” Translational Oncology 8(3):137-46 (2015). PMID: 26055170.

Boxerman JL, Schmainda KM, Zhang Z, Barboriak DP. “Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment.” Neuro Oncol 17(11):1538-9 (2015). PMID: 26361983.

Mickevicius NJ, Carle AB, Bluemel T, Santarriaga S, Schloemer F, Shumate D, Connelly J, Schmainda KM, LaViolette PS. “Location of brain tumor intersecting white matter tracts predicts patient prognosis.” J Neurooncol 125(2):393-400 (2015). PMID 26376654.

Renu D, Aggarwal P, Bhat V, Cherukuri SC, Livi C, Rosenberg M, Tata P, Al-Gizawiy M, Schmainda KM, Mirza SP. Molecular Subtypes in Glioblastoma Multiforme: Integrated Analysis using Agilent GeneSpring® Multi-Omics Software. Agilent Technologies, Inc. 2015; 5991-5505EN.

Nguyen HS, Milback N, HUrrell SL, Cochran E, Connelly J, Bovi JA, Schultz CJ, Mueller WM, Rand SD, Schmainda KM, LaViolette PS. “Progressing bevacizumab-induced diffusion restriction is associated with coagulative necrosis surrounded by viable tummor and decreased overall survival in patients with recurrent glioblastoma.” AJNR Am J Neuorradiology 37(12):2201-2208 (2016). PMID: 27492073.

McGarry SD, Hurrell SL, Kaczmarowski AL, Cochran EJ, Connelly J, Rand SD, Schmainda KM, LaViolette PS. “Magnetic resonance imaging-based radiomic profiles predict patient prognosis in newly diagnosed glioblastoma before therapy.” Tomography 2(3):223-228 (2016). PMID: 27774518.

Paulson ES, Prah DE, Schmainda KM. “Spiral perfusion imaging with consecutive echoes (SPICE) for the simultaneous mapping of DSC- and DCE-MRI parameters in brain tumor patients: theory and initial feasibility. Tomography 2(4):297-307 (2016). PMID: 28090589.